|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2011
|
|
gptkbp:chemical_formula
|
C_21 H_25 N_3 O_9 S
|
|
gptkbp:clinical_trial
|
gptkb:DRCR.net_Study
Phase III
FAME
CATT
VIEW 1
VIEW 2
VISTA
VIVID
RVO Study
TREND
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:effective_date
|
November 2011
|
|
gptkbp:frequency
|
every 4 to 8 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
EYLEA
|
|
gptkbp:indication
|
gptkb:DR
DME
RVO
wet AMD
|
|
gptkbp:ingredients
|
gptkb:aflibercept
|
|
gptkbp:invention
|
2028
|
|
gptkbp:is_a_guide_for
|
gptkb:diabetes
gptkb:American_Academy_of_Ophthalmology
gptkb:National_Institute_for_Health_and_Care_Excellence
gptkb:European_Society_of_Retina_Specialists
|
|
gptkbp:manufacturer
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:patient_population
|
adults
elderly
patients with diabetes
patients with retinal diseases
|
|
gptkbp:route_of_administration
|
intravitreal injection
|
|
gptkbp:side_effect
|
thromboembolic events
retinal detachment
eye pain
cataract
increased intraocular pressure
intraocular inflammation
hypersensitivity reactions
systemic side effects
ocular side effects
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:trade
|
gptkb:Eylea
|
|
gptkbp:used_for
|
treatment of diabetic macular edema
treatment of diabetic retinopathy
treatment of retinal vein occlusion
treatment of neovascular age-related macular degeneration
|
|
gptkbp:weight
|
600.5 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Regeneron
|
|
gptkbp:bfsLayer
|
4
|